WP 2 : A clinical characterization of treated SMA
The marketing of new therapeutics has completely changed the natural history of SMA. The objectives of this WP are to study the disease course and characteristics of treated SMA patients (WP2.1), to identify new biomarkers and measures for muscular fatigue (WP2.2) and muscular atrophy (WP2.3).
WP 2.1: Natural History: Characterization of the new induced pathology of treated SMA
Vuillerot/CICpédiatrique, Servais, Freyssenet/Millet, Schaeffer, Roche, Millet, Sysnav
WP 2.2: Implementing new biomarkers for fatigue evaluation
Vuillerot/CICpédiatrique, Servais, Millet, Roche, Sysnav
WP 2.3: Cell free biomarkers for SMA
Schaeffer, Courchet, Freyssenet, Chazaud, Gache